ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-CD19/Anti-CD3/Anti-CD28 Trispecific Antibody CC312

Its studies are mostly in Lupus Erythematosus, Systemic · Lymphoma, Non-Hodgkin, led by CytoCares.

Drug pageAnti-CD19/Anti-CD3/Anti-CD28 Trispecific Antibody CC312: every studyAll 4 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 1, since Aug 28, 20234 company-led studies, 4 open or runningNext primary completion: Sep 10, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
CytoCares44 open or runningphase 1since Aug 28, 2023Aug 28, 2023Sep 10, 2027phase 1 · NCT07177911

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 28, 2023First study: phase 1 study in Lymphoma, Non-HodgkinFirst studyNCT06037018 · 44 planned · China
  2. Jan 20, 2025Early phase 1 study in Lupus Erythematosus, SystemicNCT06888960 · 18 planned · China
  3. Sep 10, 2025Phase 1 study in Lupus Erythematosus, SystemicNCT07177911 · 32 planned · China
  4. Sep 15, 2025Early phase 1 study in Lupus Erythematosus, SystemicNCT07193810 · 6 planned · China

Ahead

  1. Nov 8, 2026Primary completion: early phase 1 study in Lupus Erythematosus, SystemicNCT06888960
  2. Sep 10, 2027Primary completion: phase 1 study in Lupus Erythematosus, SystemicNCT07177911
  3. Sep 29, 2027Primary completion: early phase 1 study in Lupus Erythematosus, SystemicNCT07193810

TargetBeta

“A trispecific T-cell engager and antibody targeting the tumor-associated antigen (TAA) CD19, the T-cell surface antigen CD3, and the T-cell specific surface glycoprotein and co-stimulatory molecule CD28, ”NCIt, by rule

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07193810Lupus Erythematosus, Systemic · ChinaEarly 1RecruitingSep 29, 20276
NCT07177911Lupus Erythematosus, Systemic · China1RecruitingSep 10, 202732
NCT06888960Lupus Erythematosus, Systemic · ChinaEarly 1RecruitingNov 8, 202618
NCT06037018Lymphoma, Non-Hodgkin · China1RecruitingMar 202644

How it is read

Names in the registry

  • “CC312”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.